Health Catalyst (HCAT) to Release Earnings on Thursday

Key Points

• Health Catalyst (HCAT) is set to release its Q2 2025 earnings after market close on August 7th, with expectations of $0.05 earnings per share and $80.59 million in revenue.
• The company's stock price opened at $3.68, with a market cap of $256.13 million and significant fluctuations over the past year, ranging from $3.49 to $9.24.
• Analysts have a mixed outlook on the stock, with a consensus rating of "Moderate Buy" and an average price target of $8.00, amid varying price target adjustments from several firms.

Health Catalyst (NASDAQ:HCAT - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect Health Catalyst to post earnings of $0.05 per share and revenue of $80.59 million for the quarter.

Health Catalyst Stock Down 3.6%

NASDAQ HCAT traded down $0.13 during trading on Friday, reaching $3.52. 718,722 shares of the company's stock traded hands, compared to its average volume of 412,937. Health Catalyst has a 12-month low of $3.48 and a 12-month high of $9.24. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.24 and a quick ratio of 1.24. The firm has a market cap of $244.99 million, a price-to-earnings ratio of -3.06 and a beta of 1.46. The company's 50 day simple moving average is $3.86 and its two-hundred day simple moving average is $4.33.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on HCAT shares. Canaccord Genuity Group cut their price objective on shares of Health Catalyst from $10.00 to $9.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. KeyCorp cut their price target on Health Catalyst from $7.00 to $5.00 and set an "overweight" rating on the stock in a report on Wednesday, April 16th. Stifel Nicolaus boosted their price target on Health Catalyst from $5.00 to $5.50 and gave the stock a "hold" rating in a research report on Thursday, May 8th. Citigroup dropped their price objective on Health Catalyst from $7.00 to $6.50 and set a "buy" rating on the stock in a research report on Friday, April 25th. Finally, BTIG Research downgraded shares of Health Catalyst from a "buy" rating to a "neutral" rating in a report on Tuesday, June 17th. Five research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $8.00.

Hedge Funds Weigh In On Health Catalyst

Several hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC increased its stake in shares of Health Catalyst by 816.8% in the first quarter. AQR Capital Management LLC now owns 168,344 shares of the company's stock worth $763,000 after acquiring an additional 149,981 shares during the period. Focus Partners Wealth purchased a new stake in Health Catalyst in the first quarter valued at $46,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Health Catalyst by 7.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company's stock valued at $163,000 after buying an additional 2,624 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company's stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.